Characterizing HDAC Pathway Copy Number Variation in Pan-Cancer

Shuming Yang1, Shengzhi Xie2, Xinying Shi3

  • 1Department of Oncology, Senior Department of Oncology, The Third Medical Center of PLA General Hospital, Beijing, China.

Summary

Histone deacetylase (HDAC) pathway copy number variation (CNV) impacts cancer progression and immune response. Altered HDAC CNV is a prognostic risk factor across multiple cancers, influencing tumor and immune characteristics.